19 results on '"Kawaoka, Yoshihiro"'
Search Results
2. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.
- Author
-
Ishizaka, Aya, Koga, Michiko, Mizutani, Taketoshi, Uraki, Ryuta, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Yamamoto, Shinya, Imai, Masaki, Tsutsumi, Takeya, Suzuki, Yutaka, Kawaoka, Yoshihiro, and Yotsuyanagi, Hiroshi
- Subjects
NASAL cavity ,IMMUNE response ,SARS-CoV-2 ,NASAL mucosa ,MESSENGER RNA ,IMMUNOGLOBULINS - Abstract
Background: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear. Methods: Here, we longitudinally analysed the changing nasal microbiota and both systemic and nasal immune response upon SARS-CoV-2 mRNA vaccination, and evaluated how mRNA vaccination influenced nasal microbiota in 18 healthy participants who had received the third BNT162b. Results: The nasal S-RBD IgG level correlated significantly with plasma IgG levels until 1 month and the levels were sustained for 3 months post-vaccination. In contrast, nasal S-RBD IgA induction peaked at 1 month, albeit slightly, and correlated only with plasma IgA, but the induction level decreased markedly at 3 months post-vaccination. 16 S rRNA sequencing of the nasal microbiota post-vaccination revealed not an overall change, but a decrease in certain opportunistic bacteria, mainly Fusobacterium. The decrease in these bacteria was more pronounced in those who exhibited nasal S-RBD IgA induction, and those with higher S-RBD IgA induction had lower relative amounts of potentially pathogenic bacteria such as Pseudomonas pre-vaccination. In addition, plasma and mucosal S-RBD IgG levels correlated with decreased commensal pathogens such as Finegoldia. Conclusions: These findings suggest that the third dose of SARS-CoV-2 mRNA vaccination induced S-RBD antibodies in the nasal mucosa and may have stimulated mucosal immunity against opportunistic bacterial pathogens. This effect, albeit probably secondary, may be considered one of the benefits of mRNA vaccination. Furthermore, our data suggest that a cooperative function of mucosal and systemic immunity in the reduction of bacteria and provides a better understanding of the symbiotic relationship between the host and bacteria in the nasal mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
- Author
-
Eiden, Joseph, Fierro, Carlos, Schwartz, Howard, Adams, Mark, Ellis, Kimberly J, Aitchison, Roger, Herber, Renee, Hatta, Yasuko, Marshall, David, Moser, Michael J, Belshe, Robert, Greenberg, Harry, Coelingh, Kathleen, Kawaoka, Yoshihiro, Neumann, Gabriele, and Bilsel, Pamuk
- Subjects
INFLUENZA vaccines ,CLINICAL trial registries ,IMMUNOGLOBULINS ,TISSUE culture ,ADULTS - Abstract
Background: We previously demonstrated that an intranasal dose of 108 TCID50 M2SR (M2-deficient single replication) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection.Methods: Sero-susceptible subjects ages 18-49 years were randomized to receive two doses (108-109TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines (ClinicalTrials.gov number NCT03999554).Results: The vaccine was well-tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% CI 24.9-56.7) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI 61.4-92.3) after 109 dose (P < 0.001). A single 109 TCID50 dose of M2SR generated ≥4-fold HAI seroconversion against the vaccine strain in 71% (95% CI 52.0-85.8) of recipients. Mucosal and cellular immune responses were also induced.Conclusions: These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. The Mechanism of Axl-Mediated Ebola Virus Infection
- Author
-
Shimojima, Masayuki, Ikeda, Yasuhiro, and Kawaoka, Yoshihiro
- Published
- 2007
- Full Text
- View/download PDF
5. M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.
- Author
-
Eiden, Joseph, Volckaert, Bram, Rudenko, Oleg, Aitchison, Roger, Herber, Renee, Belshe, Robert, Greenberg, Harry, Coelingh, Kathleen, Marshall, David, Kawaoka, Yoshihiro, Neumann, Gabriele, and Bilsel, Pamuk
- Subjects
INFLUENZA vaccines ,IMMUNOGLOBULINS ,INFLUENZA ,IMMUNITY ,RESEARCH funding ,VIRAL antibodies ,INFLUENZA A virus, H1N1 subtype ,INFLUENZA A virus, H3N2 subtype - Abstract
Background: Current influenza vaccines are strain specific and demonstrate low vaccine efficacy against H3N2 influenza disease, especially when vaccine is mismatched to circulating virus. The novel influenza vaccine candidate, M2-deficient single replication (M2SR), induces a broad, multi-effector immune response.Methods: A phase 2 challenge study was conducted to assess the efficacy of an M2SR vaccine expressing hemagglutinin and neuraminidase from A/Brisbane/10/2007 (Bris2007 M2SR H3N2; clade 1). Four weeks after vaccination, recipients were challenged with antigenically distinct H3N2 virus (A/Belgium/4217/2015, clade 3C.3b) and assessed for infection and clinical symptoms.Results: Adverse events after vaccination were mild and similar in frequency for placebo and M2SR recipients. A single dose of Bris2007 M2SR induced neutralizing antibody to the vaccine (48% of recipients) and challenge strain (27% of recipients). Overall, 54% of M2SR recipients were infected after challenge, compared with 71% of placebo recipients. The subset of M2SR recipients with a vaccine-induced microneutralization response against the challenge virus had reduced rates of infection after challenge (38% vs 71% of placebo recipients; P = .050) and reduced illness.Conclusions: Study participants with vaccine-induced neutralizing antibodies were protected against infection and illness after challenge with an antigenically distinct virus. This is the first demonstration of vaccine-induced protection against a highly drifted H3N2 challenge virus. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
- Author
-
Marzi, Andrea, Engelmann, Flora, Feldmann, Friederike, Haberthur, Kristen, Shupert, W. Lesley, Brining, Douglas, Scott, Dana P., Geisbert, Thomas W., Kawaoka, Yoshihiro, Katze, Michael G., Feldmann, Heinz, and Messaoudi, Ilhem
- Subjects
IMMUNOGLOBULINS ,HEMORRHAGIC diseases ,PRIMATES ,EBOLA virus ,BIOTERRORISM ,VESICULAR stomatitis ,CELLULAR immunity - Abstract
Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high fatality rates. These viruses pose a significant health concern worldwide due to the lack of approved therapeutics and vaccines as well as their potential misuse as bioterrorism agents. Although not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovirus glycoprotein (GP) has been shown to protect macaques from Ebola virus and Marburg virus infections, both prophylactically and postexposure in a homologous challenge setting. However, the immune mechanisms of protection conferred by this vaccine platform remain poorly understood. In this study, we set out to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection against lethal Zaire ebolavirus (ZEBOV) challenge. Groups of cynomolgus macaques were depleted of CD4+ T, CD8+ T, or CD20+ B cells before and during vaccination with rVSV/ZEBOV-GP. Unfortunately, CD20-depleted animals generated a robust IgG response. Therefore, an additional group of vaccinated animals were depleted of CD4+ T cells during challenge. All animals were subsequently challenged with a lethal dose of ZEBOV. Animals depleted of CD8+ T cells survived, suggesting a minimal role for CD8+ T cells in vaccine-mediated protection. Depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection. In contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals, indicating a minimal role for CD4+ T-cell immunity in rVSV-mediated protection. Our results suggest that antibodies play a critical role in rVSV-mediated protection against ZEBOV. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. A shared structural solution for neutralizing ebolaviruses.
- Author
-
Dias, João M, Kuehne, Ana I, Abelson, Dafna M, Bale, Shridhar, Wong, Anthony C, Halfmann, Peter, Muhammad, Majidat A, Fusco, Marnie L, Zak, Samantha E, Kang, Eugene, Kawaoka, Yoshihiro, Chandran, Kartik, Dye, John M, and Saphire, Erica Ollmann
- Subjects
MOLECULAR biology ,MONOCLONAL antibodies ,MOLECULAR cloning ,IMMUNOGLOBULINS ,VIRUSES - Abstract
Sudan virus (genus Ebolavirus) is lethal, yet no monoclonal antibody is known to neutralize it. We here describe antibody 16F6 that neutralizes Sudan virus and present its structure bound to the trimeric viral glycoprotein. Unexpectedly, the 16F6 epitope overlaps that of KZ52, the only other antibody against the GP
1,2 core to be visualized to date. Furthermore, both antibodies against this crucial epitope bridging GP1-GP2 neutralize at a post-internalization step-probably fusion. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
8. Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates.
- Author
-
Weinfurter, Jason T., Brunner, Kevin, Capuano III, Saverio V., Chengjun Li, Broman, Karl W., Kawaoka, Yoshihiro, and Friedrich, Thomas C.
- Subjects
INFLUENZA viruses ,T cells ,IMMUNOGLOBULINS ,H1N1 influenza ,CD4 antigen - Abstract
In mouse models of influenza, T cells can confer broad protection against multiple viral subtypes when antibodies raised against a single subtype fail to do so. However, the role of T cells in protecting humans against influenza remains unclear. Here we employ a translational nonhuman primate model to show that cross-reactive T cell responses play an important role in early clearance of infection with 2009 pandemic H1N1 influenza virus (H1N1pdm). To "prime" cellular immunity, we first infected 5 rhesus macaques with a seasonal human H1N1 isolate. These animals made detectable cellular and antibody responses against the seasonal H1N1 isolate but had no neutralizing antibodies against H1N1pdm. Four months later, we challenged the 5 "primed" animals and 7 naive controls with H1N1pdm. In naive animals, CD8+ T cells with an activated phenotype (Ki-67+ CD38+) appeared in blood and lung 5-7 days post inoculation (p.i.) with H1N1 pdm and reached peak magnitude 7-10 days p.i. In contrast, activated T cells were recruited to the lung as early as 2 days p.i. in "primed" animals, and reached peak frequencies in blood and lung 4-7 days p.i. Interferon (IFN)-γ Elispot and intracellular cytokine staining assays showed that the virus-specific response peaked earlier and reached a higher magnitude in "primed" animals than in naive animals. This response involved both CD4+ and CD8+ T cells. Strikingly, "primed" animals cleared H1N1pdm infection significantly earlier from the upper and lower respiratory tract than the naive animals did, and before the appearance of H1N1pdm-specific neutralizing antibodies. Together, our results suggest that cross-reactive T cell responses can mediate early clearance of an antigenically novel influenza virus in primates. Vaccines capable of inducing such cross-reactive T cells may help protect humans against severe disease caused by newly emerging pandemic influenza viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.
- Author
-
Grandea III, Andres G., Olsen, Ole A., Cox, Thomas C., Renshaw, Mark, Hammond, Philip W., Po-Ying Chan-Hui, Mitcham, Jennifer L., Cieplak, Witold, Stewart, Shaun M., Grantham, Michael L., Pekosz, Andrew, Kiso, Maki, Shinya, Kyoko, Hattae, Masato, Kawaoka, Yoshihiro, and Moyle, Matthew
- Subjects
INFLUENZA ,MONOCLONAL antibodies ,IMMUNOGLOBULINS ,B cells ,INFLUENZA A virus ,VIRUS diseases - Abstract
Influenza remains a serious public health threat throughout the world. Vaccines and antivirals are available that can provide protection from infection. However, new viral strains emerge continuously because of the plasticity of the influenza genome, which necessitates annual reformulation of vaccine antigens, and resistance to antivirals can appear rapidly and become entrenched in circulating virus populations. In addition, the spread of new pandemic strains is difficult to contain because of the time required to engineer and manufacture effective vaccines. Monoclonal antibodies that target highly conserved viral epitopes might offer an alternative protection paradigm. Herein we describe the isolation of a panel of monoclonal antibodies derived from the IgG
+ memory B cells of healthy, human subjects that recognize a previously unknown conformational epitope within the ectodomain of the influenza matrix 2 protein, M2e. This antibody binding region is highly conserved in influenza A viruses, being present in nearly all strains detected to date, including highly pathogenic viruses that infect primarily birds and swine, and the current 2009 swine-origin H1N1 pandemic strain (S-OIV). Furthermore, these human anti-M2e monoclonal antibodies protect mice from lethal challenges with either H5N1 or H1N1 influenza viruses. These results suggest that viral M2e can elicit broadly cross-reactive and protective antibodies in humans. Accordingly, recombinant forms of these human antibodies may provide useful therapeutic agents to protect against infection from a broad spectrum of influenza A strains. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
10. Binding Properties of GP1 Protein of Borna Disease Virus.
- Author
-
Makino, Akiko, Horimoto, Taisuke, and Kawaoka, Yoshihiro
- Subjects
MICROBIOLOGICAL assay ,VIROLOGY ,BORNA disease virus ,CARRIER proteins ,PROTEIN binding ,IMMUNOGLOBULINS ,GLYCOPROTEINS ,VIRUS diseases ,CELL lines - Abstract
The article presents a study that determines the binding properties of GP1 protein of Borna disease virus (BDV). Researchers carried the wild-type GP1 and a variety of GP1 deletion mutants that were FLAG-tagged at the C-terminus in human embryonic kidney 293T cells. They then purified these proteins using an anti-FLAG antibody and evaluated their ability to bind to cell lines. This study showed that GP1 bound to BDV-permissive cells but not to non-permissive cells. This protein also inhibited BDV infection via its binding to cells.
- Published
- 2009
- Full Text
- View/download PDF
11. Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.
- Author
-
Okuda, Moe, Yamayoshi, Seiya, Uraki, Ryuta, Ito, Mutsumi, Hamabata, Taiki, and Kawaoka, Yoshihiro
- Subjects
AVIAN influenza ,MAMMALS ,IMMUNOGLOBULINS ,ANTIGENS ,AMINO acids - Abstract
Highly pathogenic avian H5 influenza viruses persist among poultry and wild birds throughout the world. They sometimes cause interspecies transmission between avian and mammalian hosts. H5 viruses possessing the HA of subclade 2.3.4.4, 2.3.2.1, 2.2.1, or 7.2 were detected between 2015 and 2018. To understand the neutralizing epitopes of H5-HA, we characterized 15 human monoclonal antibodies (mAbs) against the HA of H5 viruses, which were obtained from volunteers who received the H5N1 vaccine that contains a subclade 2.2.1 or 2.1.3.2 virus as an antigen. Twelve mAbs were specific for the HA of subclade 2.2.1, two mAbs were specific for the HA of subclade 2.1.3.2, and one mAb was specific for the HA of both. Of the 15 mAbs analyzed, nine, which were specific for the HA of subclade 2.2.1, and shared the VH and VL genes, possessed hemagglutination inhibition and neutralizing activities, whereas the others did not. A single amino acid substitution or insertion at positions 144–147 in antigenic site A conferred resistance against these nine mAbs to the subclade 2.2.1 viruses. The amino acids at positions 144–147 are highly conserved among subclade 2.2.1, but differ from those of other subclades. These results show that the neutralizing epitope including amino acids at positions 144–147 is targeted by human antibodies, and plays a role in the antigenic difference between subclade 2.2.1 and other subclades. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
- Author
-
Chiba, Shiho, Halfmann, Peter J., Iida, Shun, Hirata, Yuichiro, Sato, Yuko, Kuroda, Makoto, Armbrust, Tammy, Spyra, Samuel, Suzuki, Tadaki, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNOGLOBULINS , *SARS-CoV-2 , *RECOMBINANT proteins , *GOLDEN hamster - Abstract
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a glycoprotein, expressed on the virion surface, that mediates infection of host cells by directly interacting with host receptors. As such, it is a reasonable target to neutralize the infectivity of the virus. Here we found that a recombinant S protein vaccine adjuvanted with Alhydrogel or the QS-21-like adjuvant Quil-A effectively induced anti-S receptor binding domain (RBD) serum IgG and neutralizing antibody titers in the Syrian hamster model, resulting in significantly low SARS-CoV-2 replication in respiratory organs and reduced body weight loss upon virus challenge. Severe lung inflammation upon virus challenge was also strongly suppressed by vaccination. We also found that the S protein vaccine adjuvanted with Alhydrogel, Quil-A, or an AS03-like adjuvant elicited significantly higher neutralizing antibody titers in mice than did unadjuvanted vaccine. Although the neutralizing antibody titers against the variant viruses B.1.351 and B.1.617.2 declined markedly in mice immunized with wild-type S protein, the binding antibody levels against the variant S proteins were equivalent to those against wild-type S. When splenocytes from the immunized mice were re-stimulated with the S protein in vitro, the induced Th1 or Th2 cytokine levels were not significantly different upon re-stimulation with wild-type S or variant S, suggesting that the T-cell responses against the variants were the same as those against the wild-type virus. Upon Omicron XBB-challenge in hamsters, wild-type S-vaccination with Alhydrogel or AS03 reduced lung virus titers on Day 3, and the Quil-A adjuvanted group showed less body weight loss, although serum neutralizing antibody titers against XBB were barely detected in vitro. Collectively, recombinant vaccines coupled with different adjuvants may be promising modalities to combat new variant viruses by inducing various arms of the immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
- Author
-
Chiba, Shiho, Hatta, Masato, Pattinson, David, Yasuhara, Atsuhiro, Neumann, Gabriele, and Kawaoka, Yoshihiro
- Subjects
- *
INFLUENZA A virus, H3N2 subtype , *INFLUENZA viruses , *INFLUENZA A virus , *IMMUNOGLOBULINS , *VIRUS diseases , *RECOMBINANT proteins , *FERRET - Abstract
Mutations accumulate in influenza A virus proteins, especially in the main epitopes on the virus surface glycoprotein hemagglutinin (HA). For influenza A(H3N2) viruses, in particular, the antigenicity of their HA has altered since their emergence in 1968, requiring changes of vaccine strains every few years. Most adults have been exposed to several antigenically divergent H3N2 viruses through infection and/or vaccination, and those exposures affect the immune responses of those individuals. However, animal models reflecting this 'immune history' in humans are lacking and naïve animals are generally used for vaccination and virus challenge studies. Here, we describe a ferret model to mimic the serial exposure of humans to antigenically different historical H3HA proteins. In this model, ferrets were sequentially immunized with adjuvanted recombinant H3HA proteins from two or three different H3HA antigenic clusters in chronological order, and serum neutralizing antibody titers were examined against the homologous virus and viruses from different antigenic clusters. For ferrets immunized with a single HA antigen, serum neutralizing antibody titers were elevated specifically against the homologous virus. However, after immunization with the second or third antigenically distinct HA antigen in chronological order, the ferrets showed an increase in more broadly cross-reactive neutralizing titers against the antigenically distinct viruses and against the homologous virus. Sequentially immunized animals challenged with an antigenically advanced H3N2 virus showed attenuated virus growth and less body temperature increase compared with naïve animals. These results suggest that sequential exposure to antigenically different HAs elicits broader neutralizing activity in sera and enhances immune responses against more antigenically distinct viruses Our findings may partly explain why adults who have been exposed to antigenically divergent HAs are less likely to be infected with influenza virus and have severe symptoms than children. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
- Author
-
Emi Takashita, Selya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Ito, Mutsumi, Uraki, Ryuta, Halfmann, Peter, Watanabe, Shinji, Takeda, Makoto, Hasegawa, Hideki, Imai, Masaki, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNOGLOBULINS , *ANTIVIRAL agents , *RESEARCH funding , *VIRAL antibodies - Published
- 2022
- Full Text
- View/download PDF
15. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
- Author
-
Emi Takashita, Seiya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M, Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNOGLOBULINS , *MONOCLONAL antibodies , *ANTIVIRAL agents , *VIRAL antibodies - Abstract
The article discusses The data from our trial suggest that dulaglutide , if ultimately approved for pediatric use, may offer advantages not only with regard to glycemic control but also with regard to its frequency and method of administration. Weekly administration with a device that does not require reconstitution steps or needle handling and that has shown favorable ease-of-use characteristics in preference studies involving.
- Published
- 2022
- Full Text
- View/download PDF
16. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.
- Author
-
Yamayoshi, Seiya, Yasuhara, Atsuhiro, Ito, Mutsumi, Uraki, Ryuta, and Kawaoka, Yoshihiro
- Subjects
- *
MONOCLONAL antibodies , *INFLUENZA A virus , *INFLUENZA viruses , *IMMUNOGLOBULINS , *RESPIRATORY infections - Abstract
Highlights • Influenza A viruses barely escaped from two mAbs against the HA stem. • Escape from the third anti-HA stem mAb occurred readily. • These three mAbs share an epitope and show similar potency in vitro and in vivo. Abstract Background Broadly protective human monoclonal antibodies that recognize the conserved epitopes in the HA of influenza A virus are being developed as therapeutic agents. Emergence of resistant viruses must always be considered when developing therapeutic agents against influenza. Objectives We examined human hetero-reactive mAbs against the HA stem of influenza A virus for the ease with which escape mutant viruses emerged. Study design We attempted to generate the mutant viruses escaped from the hetero-reactive anti-HA stem antibodies. We also evaluated their protective efficacy, binding affinity, and epitopes. Results We obtained several human monoclonal antibodies (mAbs) that react with the HA of different HA subtypes of influenza A virus belonging to group 1. Upon attempting to generate escape mutant viruses, we found that the ease with which such viruses emerged differed among the mAbs; viruses barely escaped from two of the mAbs (clones S9-3-37 and F20C77), whereas escape from the third mAb (clone F5B7) occurred readily. Comparisons of the mAbs revealed that the HA stem epitopes, in vitro neutralization potency, binding affinity to H1-HA, and protective efficacy against lethal challenge with H1N1pdm09 virus were all comparable. Conclusions These results demonstrate the importance of determining the ease with which escape mutant viruses emerge when evaluating anti-HA stem antibodies as antiviral agents during preclinical testing. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Protective efficacy of neutralizing antibodies against Ebola virus infection
- Author
-
Takada, Ayato, Ebihara, Hideki, Jones, Steven, Feldmann, Heinz, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNOGLOBULINS , *MOLECULAR cloning , *VIRUS diseases , *MONOCLONAL antibodies - Abstract
Abstract: Ebola virus causes lethal hemorrhagic fever in humans and nonhuman primates, but no effective antiviral compounds are available for the treatment of this infection. The surface glycoprotein (GP) of Ebola virus is an important target of neutralizing antibodies. Although passive transfer of GP-specific antibodies has been evaluated in mouse and guinea pig models, protection was achieved only by treatment shortly before or after virus challenge. Using these animal models, we evaluated the protective efficacy of two monoclonal antibodies whose epitopes are distinct from those of the antibodies tested by others. Treatment of mice with these antibodies 2 days after challenge completely protected most of the animals; even treatment 3 or 4 days after challenge was partially effective. Although antibody treatment in the guinea pig model was not as effective as in the mouse model, single-dose treatment of guinea pigs 1 day before, or 1 or 2 days after challenge did protect some animals. Interestingly, the protective effects seen in these animal models did not correlate with the in vitro neutralizing activity of the antibodies, suggesting different mechanisms of the neutralization by these antibodies. These results underscore the potential therapeutic utility of monoclonal antibodies for postexposure treatment of Ebola virus infections. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. Antibody-Dependent Enhancement of Ebola Virus Infection.
- Author
-
Takada, Ayato, Feldmann, Heinz, Ksiazek, Thomas G., and Kawaoka, Yoshihiro
- Subjects
- *
EBOLA virus disease , *IMMUNOGLOBULINS - Abstract
Examines the antibody-dependent enhancement of ebola virus infection. Mediation of enhancement by antibodies to the viral glycoprotein; Mechanism of antibody-dependent enhancement of Ebola virus infection; Outcome of Ebola outbreaks in human populations.
- Published
- 2003
- Full Text
- View/download PDF
19. RAB11A Is Essential for Transport of the Influenza Virus Genome to the Plasma Membrane.
- Author
-
Eisfeld, Amie J., Kawakami, Eiryo, Watanabe, Tokiko, Neumann, Gabriele, and Kawaoka, Yoshihiro
- Subjects
- *
INFLUENZA viruses , *CELL membranes , *IMMUNOGLOBULINS , *MICROBIAL genomes , *VIRION , *NUCLEOPROTEINS - Abstract
Influenza A virus assembly is a complex process that requires the intersection of pathways involved in transporting viral glycoproteins, the matrix protein, and viral genomes, incorporated in the viral ribonucleoprotein (vRNP) complex, to plasma membrane sites of virion formation. Among these virion components, the mechanism of vRNP delivery is the most incompletely understood. Here, we reveal a functional relationship between the cellular Rab11 GTPase isoform, RAB11A, and vRNPs and show that RAB11A is indispensable for proper vRNP transport to the plasma membrane. Using an immunofluorescence-based assay with a monoclonal antibody that recognizes nucleoprotein in the form of vRNP, we demonstrate association between RAB11A and vRNPs at all stages of vRNP cytoplasmic transport. Abrogation of RAB11A expression through small interfering RNA (siRNA) treatment or disruption of RAB11A function by overexpression of dominant negative or constitutively active proteins caused aberrant vRNP intracellular accumulation, retention in the perinuclear region, and lack of accumulation at the plasma membrane. Complex formation between RAB11A and vRNPs was further established biochemically. Our results uncover a critical host factor with an essential contribution to influenza virus genome delivery and reveal a potential role for RAB11A in the transport of ribonucleoprotein cargo. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.